Not available
Quote | Protagonist Therapeutics Inc. (NASDAQ:PTGX)
Last: | $33.72 |
---|---|
Change Percent: | 1.04% |
Open: | $34.14 |
Close: | $33.72 |
High: | $34.57 |
Low: | $33.21 |
Volume: | 777,794 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Protagonist Therapeutics Inc. (NASDAQ:PTGX)
2024-06-28 03:26:41 ET More on Prysmian S.p.A., Protagonist, etc. S&P Global, Inc.: Strong Network Effects And Sticky Products In The Non-Ratings Segment S&P Global: Strong Business Characteristics Make Them A Buy At This Price S&P Global Inc. (SPGI) Stif...
Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in ...
Message Board Posts | Protagonist Therapeutics Inc. (NASDAQ:PTGX)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $PTGX 51% v22,7M c23.09 f49,198M H23.69 ML14.93 RL15.01 gapNgo | znewcar1 | investorshangout | 03/07/2023 10:01:06 PM |
Looks like I left $3 early but made | ErnieBilco | investorshub | 03/07/2023 8:36:06 PM |
Well I let mine go today @ $20 | ErnieBilco | investorshub | 03/07/2023 6:08:53 PM |
Pulled from yahoo finance...this stock could explode 4x | ziggy7796 | investorshub | 04/27/2022 11:13:06 AM |
Just...pulled this...ziggy. Protagonist Therapeutics:Biotechnology companyP | ziggy7796 | investorshub | 04/26/2022 3:13:42 PM |
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in ...
Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide in the open-label extension of the REVIV...